NAS
CSTL icon

Nykredit A/S’s Castle Biosciences CSTL Stock Holding History

Nykredit A/S’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Buy
+597
New +$13.3K ﹤0.01% 1819

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Nykredit A/S's CSTL Position: Q2 2026 in Review

Nykredit A/S opened a new position in Castle Biosciences (CSTL) in Q2 2026: 597 shares worth $14.2K. The stake represents ﹤0.01% of the portfolio and ranks #1819 among its holdings.

125 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Nykredit A/S held 597 shares of Castle Biosciences worth $14.2K as of Q2 2026.
  • Castle Biosciences was a new Nykredit A/S position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1819 holding.
  • 125 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.